A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
Public ClinicalTrials.gov record NCT04641247. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Multicenter, Long-term Treatment Extension Study in Subjects Who Have Completed a Prior GlaxoSmithKline/TESARO-Sponsored Niraparib Study and Are Judged by the Investigator to Benefit From Continued Treatment With Niraparib
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a global extension study to provide continued access to niraparib and further characterize the long-term safety of niraparib treatment in participants who are currently receiving treatment with niraparib within GlaxoSmithKline/TESARO-sponsored studies (NCT01847274, NCT02354586, NCT01905592, NCT03308942, NCT02657889) that has fulfilled the requirements for the primary objective.
Study identification
- NCT ID
- NCT04641247
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 37 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 15, 2021
- Primary completion
- Dec 27, 2026
- Completion
- Dec 27, 2026
- Last update posted
- Jun 23, 2026
2021 – 2026
United States locations
- U.S. sites
- 13
- U.S. states
- 11
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Tucson | Arizona | 85710 | Completed |
| GSK Investigational Site | Encinitas | California | 92024 | Recruiting |
| GSK Investigational Site | Los Angeles | California | 90048 | Recruiting |
| GSK Investigational Site | Whittier | California | 90603 | Completed |
| GSK Investigational Site | Jacksonville | Florida | 32224 | Completed |
| GSK Investigational Site | Atlanta | Georgia | 30342 | Recruiting |
| GSK Investigational Site | Harvey | Illinois | 60426 | Recruiting |
| GSK Investigational Site | Boston | Massachusetts | 02115 | Recruiting |
| GSK Investigational Site | Grand Rapids | Michigan | 60637-1470 | Recruiting |
| GSK Investigational Site | Morristown | New Jersey | 07962-1956 | Recruiting |
| GSK Investigational Site | Lake Success | New York | 11042 | Recruiting |
| GSK Investigational Site | Charlotte | North Carolina | 28204 | Recruiting |
| GSK Investigational Site | Cleveland | Ohio | 44195 | Completed |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04641247, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 23, 2026 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04641247 live on ClinicalTrials.gov.